Company Description

Cellular Engineering Technologies, Inc. (CET) provides optimized reagents and human cell lines that address the technical and clinical challenges of developing next-generation cell therapies and regenerative medicines.  We offer native, human recombinant growth factors and cytokines that are designed to generate maximum cellular response and bioavailability.  Our portfolio of human somatic stem cells and induced pluripotent stem cells, programmed using our patented virus and oncogene-free methods, produce the safest and most scalable starting cell line for your research and manufacturing needs.  We also leverage our human protein expression models to create custom protein and peptide sequences.  Contact one of our application scientists today to discuss how our bioproduction and cell line engineering expertise can accelerate your drug discovery or IND-enabling activities. 
 

Company History

2000 CET launches first characterized human somatic stem cell line products for research applications.

2005 CET launches a portfolio of cell-specific media formulations to promote efficient stem cell expansion and differentiation. Our cell culture media are optimized for robust expansion and efficient differentiation with our proprietary cell lines.

2006 CET launches first induced pluripotent stem cell (iPSC) line for research applications, programmed using CET's proprietary method that is virus and oncogene-free and suitable for adherent and suspension-based cell lines.
Our non-viral methods result in efficient programming, minimal passaging, and the safest clinical risk profile for therapeutic development

2020 CET is awarded an NIH Phase II SBIR grant for "Improving the Reproducibility and Genetic Stability of IPSC and Differentiated Cells Through Oncogene-Free Reprogramming and Fully Human Growth Factors".

2022 CET manufactures first batch of human growth factor proteins from immortalized somatic stem cells.
CET's core method patent for programming iPSCs was published on March 8th.

2023 CET manufactures first batch of human growth factors from proprietary yeast lines.
CET has entered into a manufacturing partnership with the University of Iowa’s Center for Biocatalysis and Bioprocessing to manufacture cGMP-grade human growth factors.